Celldex Therapeutics, Inc. (CLDX) vs Recursion Pharmaceuticals, Inc. (RXRX)
- Celldex Therapeutics, Inc. CLDX 27.53 −4.84%
- Recursion Pharmaceuticals, Inc. RXRX 3.47 −16.59%
Celldex Therapeutics, Inc. and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Celldex Therapeutics, Inc. and Recursion Pharmaceuticals, Inc. are of similar size ($2.3B and $2.2B). Recursion Pharmaceuticals, Inc. grew revenue faster over the last twelve months: −15.1% against −88.3%. Recursion Pharmaceuticals, Inc. has the higher net margin (−945.9% vs −33,883.8%) and the lower return on invested capital (−92.2% vs 0.00%). Across the 18 metrics below, Recursion Pharmaceuticals, Inc. leads on 10 and Celldex Therapeutics, Inc. on 8.
Valuation
Profitability
| Metric | CLDX | RXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 3.48% | 65.16% |
| Operating margin | (36,733.82%) | (991.72%) | 0.00% |
| Net margin | (33,883.77%) | (945.92%) | 0.00% |
| Free cash flow margin | (27,294.81%) | (645.82%) | 0.00% |
| Return on equity | (43.88%) | (56.58%) | (56.36%) |
| Return on assets | (40.76%) | (41.26%) | (48.04%) |
| Return on invested capital | 0.00% | (92.22%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack